A detailed history of Ameriprise Financial Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 93,945 shares of LGND stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,945
Previous 100,041 6.09%
Holding current value
$10.8 Million
Previous $8.43 Million 11.64%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$82.7 - $110.11 $504,139 - $671,230
-6,096 Reduced 6.09%
93,945 $9.41 Million
Q2 2024

Aug 14, 2024

SELL
$68.53 - $87.91 $1.11 Million - $1.43 Million
-16,252 Reduced 13.98%
100,041 $8.43 Million
Q1 2024

May 15, 2024

BUY
$68.64 - $89.2 $667,043 - $866,845
9,718 Added 9.12%
116,293 $8.5 Million
Q4 2023

Feb 14, 2024

SELL
$49.57 - $72.63 $1.43 Million - $2.1 Million
-28,868 Reduced 21.31%
106,575 $7.61 Million
Q3 2023

Nov 14, 2023

SELL
$58.86 - $72.67 $626,917 - $774,008
-10,651 Reduced 7.29%
135,443 $8.12 Million
Q2 2023

Aug 14, 2023

BUY
$69.53 - $79.33 $943,243 - $1.08 Million
13,566 Added 10.24%
146,094 $10.5 Million
Q1 2023

May 15, 2023

SELL
$65.67 - $77.08 $167,392 - $196,476
-2,549 Reduced 1.89%
132,528 $9.75 Million
Q4 2022

Feb 14, 2023

SELL
$61.72 - $96.74 $551,529 - $864,468
-8,936 Reduced 6.2%
135,077 $9.02 Million
Q3 2022

Nov 14, 2022

SELL
$0.01 - $107.56 $61 - $658,159
-6,119 Reduced 4.08%
144,013 $12.4 Million
Q2 2022

Aug 15, 2022

BUY
$74.52 - $117.06 $2.89 Million - $4.54 Million
38,784 Added 34.83%
150,132 $13.4 Million
Q1 2022

May 16, 2022

SELL
$94.99 - $151.56 $66,682 - $106,395
-702 Reduced 0.63%
111,348 $12.5 Million
Q4 2021

Feb 14, 2022

BUY
$127.69 - $165.85 $169,061 - $219,585
1,324 Added 1.2%
112,050 $17.3 Million
Q3 2021

Nov 15, 2021

BUY
$102.33 - $144.73 $2 Million - $2.84 Million
19,590 Added 21.5%
110,726 $15.4 Million
Q2 2021

Aug 16, 2021

SELL
$113.03 - $155.64 $115,516 - $159,064
-1,022 Reduced 1.11%
91,136 $12 Million
Q1 2021

May 17, 2021

SELL
$99.52 - $215.83 $7.56 Million - $16.4 Million
-76,011 Reduced 45.2%
92,158 $14.1 Million
Q4 2020

Feb 12, 2021

SELL
$80.55 - $106.05 $3.08 Million - $4.05 Million
-38,185 Reduced 18.5%
168,169 $16.7 Million
Q3 2020

Nov 16, 2020

SELL
$89.56 - $126.72 $22.4 Million - $31.7 Million
-250,272 Reduced 54.81%
206,354 $19.7 Million
Q2 2020

Aug 14, 2020

BUY
$68.28 - $123.65 $8.55 Million - $15.5 Million
125,265 Added 37.8%
456,626 $51.1 Million
Q1 2020

May 15, 2020

BUY
$63.37 - $107.88 $1.48 Million - $2.52 Million
23,327 Added 7.57%
331,361 $24.1 Million
Q4 2019

Feb 14, 2020

SELL
$96.94 - $113.59 $2.32 Million - $2.72 Million
-23,938 Reduced 7.21%
308,034 $32.1 Million
Q3 2019

Nov 14, 2019

BUY
$86.25 - $120.16 $1.69 Million - $2.36 Million
19,629 Added 6.28%
331,972 $33 Million
Q2 2019

Aug 14, 2019

SELL
$107.38 - $129.34 $1.96 Million - $2.37 Million
-18,297 Reduced 5.53%
312,343 $35.6 Million
Q1 2019

May 15, 2019

SELL
$105.93 - $142.47 $37.6 Million - $50.6 Million
-355,358 Reduced 51.8%
330,640 $41.6 Million
Q4 2018

Feb 14, 2019

BUY
$128.36 - $272.13 $5.35 Million - $11.3 Million
41,686 Added 6.47%
685,998 $93.1 Million
Q3 2018

Nov 14, 2018

SELL
$211.18 - $274.49 $25.5 Million - $33.2 Million
-120,857 Reduced 15.79%
644,312 $177 Million
Q2 2018

Aug 14, 2018

SELL
$150.77 - $207.98 $1.1 Million - $1.52 Million
-7,325 Reduced 0.95%
765,169 $159 Million
Q1 2018

May 15, 2018

BUY
$138.63 - $182.62 $50.6 Million - $66.7 Million
365,122 Added 89.63%
772,494 $128 Million
Q4 2017

Feb 12, 2018

BUY
$128.36 - $147.04 $3.01 Million - $3.45 Million
23,453 Added 6.11%
407,372 $55.8 Million
Q3 2017

Nov 07, 2017

BUY
$120.91 - $137.94 $46.4 Million - $53 Million
383,919
383,919 $52.3 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.94B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.